• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biocept Inc (NQ: BIOC )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Oct 24, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Biocept Inc

    < Previous 1 2 3 Next >
    Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
    From Biocept, Inc.
    Via Business Wire
    Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
    From Biocept, Inc.
    Via Business Wire
    Biocept Inc. (NASDAQ: BIOC) Near the Top of Equities by Percentage Gain on 5/19
    Via Investor Brand Network
    Biocept to Participate in the H.C. Wainwright Global Investment Conference
    From Biocept, Inc.
    Via Business Wire
    Biocept to Hold Business Update Conference Call on August 30, 2023
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Second Quarter 2023 Financial Results
    From Biocept, Inc.
    Via Business Wire
    Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces the Passing of Board Chair M. Faye Wilson
    From Biocept, Inc.
    Via Business Wire
    Biocept Names Antonino Morales as President and Chief Executive Officer
    From Biocept, Inc.
    Via Business Wire
    Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology
    From Biocept, Inc.
    Via Business Wire
    BioMedNewsBreaks – Biocept Inc. (NASDAQ: BIOC) Releases Pricing on Public Offering
    Via Investor Brand Network
    Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces One-for-Thirty Reverse Stock Split
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports First Quarter 2023 Financial Results
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports 2022 Financial Results
    From Biocept, Inc.
    Via Business Wire
    Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Biocept, Inc.
    Via Business Wire
    Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Third Quarter 2022 Financial Results
    From Biocept, Inc.
    Via Business Wire
    Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Second Quarter 2022 Financial Results
    From Biocept, Inc.
    Via Business Wire
    Biocept to Present at the LD Micro Main Event XV
    From Biocept, Inc.
    Via Business Wire
    Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
    From Biocept, Inc.
    Via Business Wire
    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
    From Biocept, Inc.
    Via Business Wire
    Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
    From Biocept, Inc.
    Via Business Wire
    Biocept Appoints RSM as Independent Auditor
    From Biocept, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.